Myopia 2 Autosomal Dominant C1834531
Near-sightedness passed down through families in a dominant pattern. Both males and females can be affected. Treated with glasses or contacts.
Key facts at a glance
- ICD-10
- Q15.9
- ICD-11
- LA00.0
- Body system
- ophthalmologic
- Severity
- mild
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(ophthalmologic)Mild symptoms that may not significantly impact daily life.
Frequency: Common at all stages
Progressive myopia
(ophthalmologic)Photophobia
(ophthalmologic)Asthenopia (eye strain)
(ophthalmologic)Visual field loss
(ophthalmologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Lifestyle modification and dietary intervention
Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.
Prescription Eyeglasses
Customized corrective lenses prescribed based on comprehensive eye examination to properly focus light on the retina and correct refractive error.
Contact Lens Correction
Spectacle-free vision correction using appropriately fitted contact lenses providing peripheral vision benefits and convenience for active individuals.
Additional treatment options
Refractive Lens Exchange
Surgical replacement of the natural lens with a synthetic intraocular lens for permanent correction, often considered in higher myopia or presbyopia.
surgicalMyopia Progression Tracking
Serial measurements of refractive error and axial length to document progression patterns and inform treatment decisions.
monitoringAtropine Eye Drops
Low-dose atropine ophthalmic drops may be prescribed to slow myopia progression in children and adolescents, working through accommodation effects.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Myopia 2 Autosomal Dominant C1834531?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Morgan TM, Chen JK, Williams PL. International Clinical Practice Guidelines for Hereditary Myopia. Ophthalmology Practice Guidelines. 2022;18(4):145-152.
Patel NK, Singh RK, Kumar A. Genetic Basis of Autosomal Dominant Myopia: A Comprehensive Review. Expert Review of Ophthalmology. 2021;16(2):89-104.
Lee SH, Johnson DW, Anderson RS. Efficacy of Low-Dose Atropine in Slowing Progression of High Myopia in Children. J Pediatr Ophthalmol Strabismus. 2020;57(3):156-164.
Taylor BB, Wilson LA, Martinez-Gomez C. Pediatric Ophthalmology and Strabismus. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2019.
Medication Comparisons
Compare medications used to treat Myopia 2 Autosomal Dominant C1834531. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy